— Know what they know.
Not Investment Advice

RNAM NASDAQ

Avidity Biosciences Inc
1W: -1.9% 1M: -1.7% YTD: -1.8%
$72.86
Last traded 2026-03-03 — delisted
NASDAQ · Healthcare · Biotechnology · $11.3B mcap · 132M float · 2.04% daily turnover · Short 27% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$11.3B
52W Range21.51-73.06
Volume1
Avg Volume2,697,504
Beta0.93
Dividend
Analyst Ratings
2 Buy 9 Hold 0 Sell
Consensus Hold
Company Info
CEOSarah Boyce
Employees511
SectorHealthcare
IndustryBiotechnology
IPO Date2020-06-12
3020 Callan Road
San Diego, CA 92121
US
1 858 401 7900
About Avidity Biosciences Inc

Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.

Recent Insider Trades

NameTypeSharesPriceDate
McCarthy Teresa D-Return 78,000 $10.16 2026-02-27
McCarthy Teresa D-Return 165,296 2026-02-27
McCarthy Teresa D-Return 106,000 $29.00 2026-02-27
McCarthy Teresa D-Return 65,000 $22.34 2026-02-27
McCarthy Teresa D-Return 50,000 $31.42 2026-02-27

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms